Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of the Vega Healthcare Provider Report on Provider Satisfaction and Decision-Making Confidence in Simulated Patient Portal Visits for Migraine
Headache
Headache Posters (7:00 AM-5:00 PM)
143

To evaluate satisfaction with the healthcare provider report (HPR) from a migraine smartphone app (Vega), and its impact on provider confidence in decision-making in simulated patient portal communications.

Patient portals of many electronic health records (EHRs) allow patients to securely send time-sensitive questions to providers, who frequently require further clarifying questions following EHR review to make informed decisions. Vega allows patients to log migraine-related data and medication usage in real-time and compile these into an HPR to facilitate patient-provider communication and decision-making confidence in care.

Twelve Mass General Brigham providers (neurologists and primary care) received 10 standardized simulated cases mimicking typical patient portal communications after an initial visit, accompanied by EHR data (medical history, physical, laboratory/imaging data, and initial assessment and plan). For each provider, cases were randomized 1:1 so that half included a Vega HPR. Providers sent their medical decisions to a proctor, who provided additional information if requested. After each case, providers scored their confidence in their decision and satisfaction with the Vega HPR on a 5-point Likert scale (5=most confident /satisfied). Mean confidence scores of the Vega HPR and Non-HPR groups were compared using a linear mixed effect model, and mean satisfaction score for the Vega HPRs was calculated.

The mean confidence scores for Non-HPR and Vega HPR cases were 3.88 (95% CI, 3.53-4.23) and 4.40 (95% CI, 4.05-4.75), respectively. The difference between means was 0.517 (95% CI, 0.21-0.83, p=0.0013), demonstrating that access to a Vega HPR improved provider confidence in their medical decision. Mean satisfaction with the Vega HPR was 4.633 (SD 0.663, IQR 1, median 5) out of 5, indicating high satisfaction with the reports.

Providers responding to simulated patient portal encounters with the additional Vega HPR data were more confident in their decision-making and reported a high level of satisfaction with the HPR.

Authors/Disclosures
Paul B. Rizzoli, MD, FÂé¶¹´«Ã½Ó³»­ (BW/F Neurology)
PRESENTER
Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome. Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Rizzoli has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Rizzoli has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Harvard Health Publishing. The institution of Dr. Rizzoli has received research support from Abbvie. Dr. Rizzoli has received publishing royalties from a publication relating to health care.
Melissa Darsey, PA (Brigham and Women's Hospital) Melissa Darsey has a non-compensated relationship as a Clinical Research Assistant with Allergan that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Bert B. Vargas, MD, FÂé¶¹´«Ã½Ó³»­ (Eli Lilly and Company) Dr. Vargas has received personal compensation for serving as an employee of Lilly USA. Dr. Vargas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Football League. Dr. Vargas has or had stock in Eli Lilly. An immediate family member of Dr. Vargas has or had stock in Pfizer.Dr. Vargas has received personal compensation in the range of $500-$4,999 for serving as a Unaffiliated Neurotrauma Consultant with National Football League. Dr. Vargas has received personal compensation in the range of $10,000-$49,999 for serving as a Neurotrauma Consultant with National Association for Stock Car Auto Racing.